Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets

Posted on:09 Jul 2016 09:14:58
Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets
09 July 2016 Current Affairs: Zydus Cadila, a leading global healthcare firm, on 7 July 2016 inked a non-exclusive, royalty free agreement with the Medicines Patent Pool (MPP). Under the pact they will be manufacturing global pharma major Bristol-Myers Squibb’s daclatasvir tablets used for the treatment of Hepatitis C Virus (HCV).

Bristol-Myers Squibb’s daclatasvir is a novel direct-acting antiviral (DAA) that is proven to help cure multiple genotypes of HCV.

The agreement sub-licences Zydus to produce and sell daclatasvir in 112 low and middle income countries. Between 130 and 150 million people worldwide are estimated to have HCV.

The MPP licence allows generic manufacturers to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Daclatasvir, in combination with other DAAs, for example sofosbuvir, produces high cure rates after 12 weeks of treatment, with recent Phase III studies demonstrating  that  the  regimen  could  cure  up  to  100%  of  HCV  patients  depending  on genotype and stage of liver disease.

Zydus Cadila : Zydus  Cadila  is  an  innovative,  global  pharmaceutical  company  that  discovers,  develops, manufactures and markets a broad range of healthcare therapies. The group launched its own patented NCE –Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

It also launched ‘Exemptia’ the world’s first biosimilar of Adalimumab for the treatment  of  inflammatory  arthritis,  Ulcerative  Colitis  and  Crohn’s  Disease  in  adult  & paediatric  patients.  The group aspires to be a research-based pharmaceutical company by 2020. The group employs over 19000 people worldwide.

Monthly Current Affairs

Current Affairs Section

Daily Current Affairs Quiz

Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs November 2017

22 NOVEMBER
NEWS
21 NOVEMBER
NEWS
20 NOVEMBER
NEWS
19 NOVEMBER
NEWS

Current Affairs October 2017

31 OCTOBER
NEWS
30 OCTOBER
NEWS
29 OCTOBER
NEWS
28 OCTOBER
NEWS

Current Affairs September 2017

30 SEPTEMBER
NEWS
28 SEPTEMBER
NEWS
27 SEPTEMBER
NEWS
26 SEPTEMBER
NEWS